Full-Time

Business Performance Manager

Amgen External Planning

Updated on 8/24/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, PhD

Category
Operations & Logistics (1)
Required Skills
Power BI
Supply Chain Management
GMP
SAP Products
Tableau
Business Analytics
Data Analysis
Financial Modeling

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree and at least 3 years of experience in supply chain, business analytics, or operations; or a master's degree and at least 8 years of such experience; or a bachelor's degree and at least 10 years of such experience.
  • At least 2 years of experience directly managing or leading projects or programs.
  • Experience in pharmaceutical or biotechnology supply chain, particularly within good manufacturing practice-regulated environments.
  • Strong understanding of external manufacturing operations involving contract manufacturing organizations or contract development and manufacturing organizations.
  • Experience building performance dashboards and key performance indicator governance frameworks.
  • Experience supporting Quarterly Business Reviews, Integrated Business Planning, or Long-Range Strategy cycles.
  • Strong financial acumen, including cost-to-serve, productivity, and capacity modeling.
  • Familiarity with SAP, Rapid Response, Power BI or Tableau, and enterprise planning systems.
  • Ability to translate data into executive-ready insights.
  • Ability to understand complex processes, derive insights, and visualize end-to-end workflows.
  • Ability to operate effectively across multiple global time zones and matrix organizations.
Responsibilities
  • Own, shape, and deliver the AXP digital strategy, solutions, and transformation initiatives.
  • Support the performance and usability of end-to-end AXP business reporting tools and key performance indicator dashboards.
  • Support development and continuous improvement of tools used for supply dashboards and metrics.
  • Ensure visibility into key performance drivers, including data accuracy and application usability for commercial and clinical functions.
  • Support system usage and improvements for Quarterly Business Reviews and forward 12-quarter strategy discussions.
  • Partner with Finance and Global Planning to align performance metric platforms for financial and long-range strategy cycles.
  • Own the AXP Process Framework and Operating Model across Plan, Source, Make, Deliver, and Enable.
  • Complete continuous improvement, risk identification, and value stream mapping of existing process maps, RACI documents, work instructions, job aids, and guide documents.
  • Manage changes to standard operating procedures and approved documentation in collaboration with AXP Compliance and the Business Development Office.
  • Evaluate the success of process changes in collaboration with the AXP Business Development Office.
  • Partner with AXP operations across the United States, Europe, and JAPAC regions to align priorities.
  • Partner with Amgen Digital and Technology teams to advance scalable, technology-enabled analytics solutions.
  • Partner with Global, Regional, and Site Supply Chain, Global Distribution, Operations Finance, External Supply Quality, and Global Planning stakeholders.
  • Support evolution toward a digitally integrated, insight-driven operating model.
  • Contribute to continuous improvement initiatives and operating model refinement across AXP.
  • Lead, coach, and develop team members in the area of expertise.
  • Support talent development, capability building, succession planning, and employee engagement initiatives.
  • Support strategic initiatives, digital transformation efforts, and automation opportunities across the AXP organization.
  • Work under minimal direction on department strategy and operational and project objectives.
  • Manage multiple assignments and processes simultaneously, determining approaches to initiatives, projects, and issue resolution.
  • Identify solutions for complex problems and advise leadership on options and risks related to program or project objectives.
  • Develop robust, practical solutions aligned with functional objectives.
  • Establish relationships to identify needs, requirements, and opportunities.
  • Extend capabilities by working with senior staff and subject-matter experts inside and outside the organization.
Desired Qualifications
  • Proven leadership capabilities with strong written, verbal, and presentation skills.
  • Experience leading cross-functional improvement initiatives.
  • Proven success in project management, ideally for supply chain or information systems projects.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.